{"id":745556,"date":"2017-05-10T16:39:00","date_gmt":"2017-05-10T16:39:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-mercks-keytruda-pembrolizumab-as-first-line-combination-therapy-with-pemetrexed-and-carboplatin-for-patients-with-metastatic-nonsquamous-non-small-cell-lung-cancer-nsclc\/"},"modified":"2025-11-07T01:26:32","modified_gmt":"2025-11-07T06:26:32","slug":"fda-approves-mercks-keytruda-pembrolizumab-as-first-line-combination-therapy-with-pemetrexed-and-carboplatin-for-patients-with-metastatic-nonsquamous-non-small-cell-lung-cancer-nsclc","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-mercks-keytruda-pembrolizumab-as-first-line-combination-therapy-with-pemetrexed-and-carboplatin-for-patients-with-metastatic-nonsquamous-non-small-cell-lung-cancer-nsclc\/","title":{"rendered":"FDA Approves Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) as First-Line Combination Therapy with Pemetrexed and Carboplatin for Patients with Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC), Irrespective of PD-L1 Expression"},"content":{"rendered":"<p class=\"bwalignc\">       First Approval for an Anti-PD-1 Therapy as a Combination in        Metastatic Nonsquamous NSCLC     <\/p>\n<p>\n      Merck (NYSE: MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced that the U.S. Food and Drug Administration (FDA) has<br \/>\n      approved KEYTRUDA<sup>\u00ae<\/sup> (pembrolizumab), the company\u2019s anti-PD-1<br \/>\n      therapy, in combination with pemetrexed (brand name Alimta<sup>\u00ae<\/sup>)<br \/>\n      and carboplatin (pem\/carbo), a commonly used chemotherapy regimen, for<br \/>\n      the first-line treatment of metastatic nonsquamous NSCLC, irrespective<br \/>\n      of PD-L1 expression. Under the FDA\u2019s accelerated approval regulations,<br \/>\n      this indication is approved based on tumor response rate and<br \/>\n      progression-free survival (PFS). Continued approval for this indication<br \/>\n      may be contingent upon verification and description of clinical benefit<br \/>\n      in the confirmatory trials.\n    <\/p>\n<p>\n      The approval was based on data from KEYNOTE-021, Cohort G1, in 123<br \/>\n      previously untreated patients with metastatic nonsquamous NSCLC with no<br \/>\n      EGFR or ALK genomic tumor aberrations and irrespective of PD-L1<br \/>\n      expression. In this trial, KEYTRUDA + pem\/carbo demonstrated an<br \/>\n      objective response rate (ORR) that was nearly double the ORR of<br \/>\n      pem\/carbo alone (55 percent [95% CI: 42, 68] compared to 29 percent [95%<br \/>\n      CI: 18, 41], respectively; all responses were partial responses). Among<br \/>\n      patients who received KEYTRUDA + pem\/carbo, 93 percent had a duration of<br \/>\n      response of six months or more (range 1.4+ to 13.0+ months) compared to<br \/>\n      81 percent who received pem\/carbo alone (range 1.4+ to 15.2+ months). In<br \/>\n      addition, findings demonstrated an improvement in PFS (HR 0.53 [95% CI,<br \/>\n      0.31-0.91; p=0.0205]), with a median PFS of 13.0 months (95% CI, 8.3-not<br \/>\n      estimable) for patients treated with KEYTRUDA + pem\/carbo compared to<br \/>\n      8.9 months (95% CI, 4.4-10.3) with pem\/carbo alone.\n    <\/p>\n<p>\n      Immune-mediated adverse reactions occurred with KEYTRUDA including<br \/>\n      pneumonitis, colitis, hepatitis, endocrinopathies, and nephritis. Based<br \/>\n      on the severity of the adverse reaction, KEYTRUDA should be withheld or<br \/>\n      discontinued and corticosteroids administered when appropriate. KEYTRUDA<br \/>\n      can also cause severe or life-threatening infusion-related reactions.<br \/>\n      Monitor patients for signs and symptoms of infusion-related reactions;<br \/>\n      for Grade 3 or 4 reactions, stop infusion and permanently discontinue<br \/>\n      KEYTRUDA (pembrolizumab). Based on its mechanism of action, KEYTRUDA can<br \/>\n      cause fetal harm when administered to a pregnant woman. Female patients<br \/>\n      of reproductive potential should be advised of the potential hazard to a<br \/>\n      fetus. For more information regarding immune-mediated and<br \/>\n      infusion-related adverse reactions and use in pregnancy, see \u201cSelected<br \/>\n      Important Safety Information\u201d below.\n    <\/p>\n<p>\n      \u201cThe improved responses seen with the KEYTRUDA plus<br \/>\n      pemetrexed\/carboplatin regimen are significant, and highlight the<br \/>\n      importance of finding new approaches that address the unmet needs of<br \/>\n      patients with metastatic nonsquamous non-small cell lung cancer,\u201d said<br \/>\n      Dr. Roger M. Perlmutter, president, Merck Research Laboratories.<br \/>\n      \u201cToday\u2019s approval further supports our commitment to improve the lives<br \/>\n      of people with cancer.\u201d\n    <\/p>\n<p>\n      \u201cThis approval marks an important milestone in the treatment of lung<br \/>\n      cancer. Now, pembrolizumab in combination with pemetrexed and<br \/>\n      carboplatin can be prescribed in the first-line setting for patients<br \/>\n      with metastatic nonsquamous non-small cell lung cancer, irrespective of<br \/>\n      PD-L1 expression,\u201d said Dr. Corey Langer, director of thoracic oncology<br \/>\n      and professor of medicine at the Hospital of the University of<br \/>\n      Pennsylvania. \u201cPhysicians should continue to use each patient\u2019s<br \/>\n      individual characteristics \u2013 including biomarker status, histology, and<br \/>\n      other clinical factors \u2013 to determine the best treatment plan for each<br \/>\n      person.\u201d\n    <\/p>\n<p>\n      The combination therapy indication makes KEYTRUDA an option for more<br \/>\n      patients. KEYTRUDA is the only anti-PD-1 approved in the first-line<br \/>\n      setting as both monotherapy and combination therapy for appropriate<br \/>\n      patients with metastatic NSCLC. KEYTRUDA is approved as monotherapy in<br \/>\n      the first-line setting for patients with metastatic NSCLC whose tumors<br \/>\n      have high PD-L1 expression (tumor proportion score [TPS] \u226550%) as<br \/>\n      determined by an FDA-approved test, with no EGFR or ALK genomic tumor<br \/>\n      aberrations. KEYTRUDA as monotherapy is also indicated for the<br \/>\n      second-line or greater treatment of patients with metastatic NSCLC whose<br \/>\n      tumors express PD-L1 (TPS \u22651%) as determined by an FDA-approved test,<br \/>\n      with disease progression on or after platinum-containing chemotherapy.<br \/>\n      Patients with EGFR or ALK genomic tumor aberrations should have disease<br \/>\n      progression on FDA-approved therapy for these aberrations prior to<br \/>\n      receiving KEYTRUDA.\n    <\/p>\n<p>\n      \u201cThe combination of this immunotherapy with pemetrexed and carboplatin<br \/>\n      is more good news for patients,\u201d said Bonnie J. Addario, a lung cancer<br \/>\n      survivor and founder of the Bonnie J. Addario Lung Cancer Foundation.<br \/>\n      \u201cCongratulations to Merck and the FDA for moving so swiftly on this<br \/>\n      important addition to our patients\u2019 options for treatment. With this<br \/>\n      approval, hope for lung cancer patients continues to improve.\u201d\n    <\/p>\n<p>\n      <b>Data Supporting the Approval<\/b>\n    <\/p>\n<p>\n      The efficacy of KEYTRUDA (pembrolizumab) was investigated in patients<br \/>\n      enrolled in the open-label, multicenter, multi-cohort KEYNOTE-021 study;<br \/>\n      the efficacy data are limited to patients with metastatic nonsquamous<br \/>\n      NSCLC randomized within the single cohort (Cohort G1). The KEYNOTE-021G1<br \/>\n      trial was conducted in collaboration with Eli Lilly and Company, the<br \/>\n      maker of pemetrexed. The key eligibility criteria for this cohort were<br \/>\n      locally advanced or metastatic nonsquamous NSCLC, regardless of tumor<br \/>\n      PD-L1 expression status, and no prior systemic treatment for metastatic<br \/>\n      disease. Patients with autoimmune disease that required systemic therapy<br \/>\n      within two&nbsp;years of treatment; a medical condition that required<br \/>\n      immunosuppression; or who had received more than 30&nbsp;Gy of thoracic<br \/>\n      radiation within the prior 26&nbsp;weeks were ineligible. Patients in<br \/>\n      KEYNOTE-021G1 were randomized to receive KEYTRUDA + pem\/carbo (n=60) or<br \/>\n      pem\/carbo alone (n=63). Patients in the KEYTRUDA combination arm<br \/>\n      received KEYTRUDA (200 mg), pemetrexed (500 mg\/m<sup>2<\/sup>), and<br \/>\n      carboplatin (AUC 5 mg\/mL\/min) every three weeks for four cycles followed<br \/>\n      by KEYTRUDA every three weeks. In the control arm, patients received<br \/>\n      pemetrexed (500 mg\/m<sup>2<\/sup>) and carboplatin (AUC 5 mg\/mL\/min)<br \/>\n      alone for four cycles. At the investigator\u2019s discretion, maintenance<br \/>\n      pemetrexed (500 mg\/m<sup>2<\/sup>) every three weeks was permitted in<br \/>\n      both treatment arms. Treatment with KEYTRUDA continued until Response<br \/>\n      Evaluation Criteria in Solid Tumors (RECIST) 1.1-defined progression of<br \/>\n      disease as determined by blinded independent central review (BICR),<br \/>\n      unacceptable toxicity, or a maximum of 24 months. Administration of<br \/>\n      KEYTRUDA was permitted beyond RECIST-defined disease progression if the<br \/>\n      patient was clinically stable and deriving clinical benefit as<br \/>\n      determined by the investigator.\n    <\/p>\n<p>\n      The major efficacy outcome measure was ORR as assessed by BICR using<br \/>\n      RECIST 1.1. Additional efficacy outcome measures were PFS as assessed by<br \/>\n      BICR using RECIST 1.1, duration of response, and overall survival (OS).\n    <\/p>\n<p>\n      Findings from this cohort demonstrated an ORR with KEYTRUDA + pem\/carbo<br \/>\n      of 55 percent (95% CI: 42, 68) compared to 29 percent (95% CI: 18, 41)<br \/>\n      for pem\/carbo alone. KEYTRUDA in this combination also reduced the risk<br \/>\n      of disease progression or death by 47 percent (HR, 0.53 [95% CI, 0.31,<br \/>\n      0.91]; p=0.0205).\n    <\/p>\n<p>\n      Exploratory analyses found similar results in patients with or without<br \/>\n      PD-L1 expression, with an ORR in patients whose tumors did not express<br \/>\n      PD-L1 (TPS &lt;1%) of 57 percent with KEYTRUDA + pem\/carbo compared to 13.0<br \/>\n      percent with pem\/carbo alone; in patients with PD-L1 TPS \u22651%, the ORR<br \/>\n      was 54 percent with KEYTRUDA + pem\/carbo compared to 38 percent with<br \/>\n      pem\/carbo alone.\n    <\/p>\n<p>\n      Efficacy Results from KEYNOTE-021, Cohort G1\n    <\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tbody>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          <b>Endpoint<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            <b>KEYTRUDA + Pem\/Carbo<\/b>\n<\/p>\n<p class=\"bwcellpmargin\">\n            <b>(n=60)<\/b>\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            <b>Pem\/Carbo<\/b>\n<\/p>\n<p class=\"bwcellpmargin\">\n            <b>(n=63)<\/b>\n          <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl bwsinglebottom\">\n          <b>Overall Response Rate<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignt bwalignl bwsinglebottom\">\n          Overall Response Rate\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          55%\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          29%\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignt bwalignl bwsinglebottom\">\n          (95% CI)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          (42, 68)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          (18, 41)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8  bwvertalignt bwalignl bwsinglebottom\">\n          Complete Response\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          0%\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          0%\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8  bwvertalignt bwalignl bwsinglebottom\">\n          Partial Response\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          55%\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          29%\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignt bwalignl bwsinglebottom\">\n          p-value*\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\" colspan=\"5\">\n          0.0032\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl bwsinglebottom\">\n          <b>Duration of Response<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignt bwalignl bwsinglebottom\">\n          % with duration \u22656-months<sup>\u2020<\/sup>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          93%\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          81%\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignt bwalignl bwsinglebottom\">\n          Range (months)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          1.4+ to 13.0+\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          1.4+ to 15.2+\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl bwsinglebottom\">\n          <b>PFS<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignt bwalignl bwsinglebottom\">\n          Number of events (%)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          23 (38%)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          33 (52%)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8  bwvertalignt bwalignl bwsinglebottom\">\n          Progressive Disease\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          15 (25%)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          27 (43%)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8  bwvertalignt bwalignl bwsinglebottom\">\n          Death\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          8 (13%)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          6 (10%)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignt bwalignl bwsinglebottom\">\n          Median in months (95% CI)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          13.0 (8.3, NE)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          8.9 (4.4, 10.3)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignt bwalignl bwsinglebottom\">\n          Hazard ratio<sup>\u2021<\/sup> (95% CI)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\" colspan=\"5\">\n          0.53 (0.31, 0.91)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignt bwalignl bwsinglebottom\">\n          p-value<sup>\u00a7<\/sup>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\" colspan=\"5\">\n          0.0205\n        <\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tbody>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">\n          *\n        <\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">\n          Based on Miettinen-Nurminen method stratified by PD-L1 status (TPS &lt;<br \/>\n          1% vs. TPS \u2265 1%)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">\n          <sup>\u2020<\/sup>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">\n          Based on Kaplan-Meier estimation\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">\n          <sup>\u2021<\/sup>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">\n          Based on the Cox proportional hazard model stratified by PD-L1<br \/>\n          status (TPS &lt; 1% vs. TPS \u2265 1%)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">\n          \u00a7\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">\n          Based on the log-rank test stratified by PD-L1 status (TPS &lt; 1% vs.<br \/>\n          TPS \u2265 1%)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\" colspan=\"3\">\n<p class=\"bwcellpmargin\">\n            NE = not estimable\n          <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td colspan=\"3\">\n          &nbsp;\n        <\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>\n      In the KEYNOTE-021G1 trial, safety was evaluated in 59 patients who<br \/>\n      received KEYTRUDA (pembrolizumab) + pem\/carbo and 62 patients who<br \/>\n      received pem\/carbo alone. KEYNOTE-021 was not designed to demonstrate a<br \/>\n      statistically significant difference in adverse reaction rates for<br \/>\n      KEYTRUDA plus chemotherapy, as compared to chemotherapy alone, for any<br \/>\n      specified adverse reaction listed in the chart below.\n    <\/p>\n<p>\n      KEYTRUDA was discontinued for adverse reactions in 10 percent of<br \/>\n      patients. The most common adverse reaction resulting in discontinuation<br \/>\n      of KEYTRUDA (\u22652%) was acute kidney injury (3.4%). Adverse reactions<br \/>\n      leading to interruption of KEYTRUDA occurred in 39% of patients; the<br \/>\n      most common (\u22652%) were fatigue (8%), neutrophil count decreased (8%),<br \/>\n      anemia (5%), dyspnea (3.4%), and pneumonitis (3.4%).\n    <\/p>\n<p>\n      Adverse Reactions Occurring in \u226520% of Patients in KEYNOTE-021, Cohort G1\n    <\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tbody>\n<tr>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\" colspan=\"4\">\n<p class=\"bwcellpmargin\">\n            <b>KEYTRUDA + Pem\/Carbo<\/b>\n<\/p>\n<p class=\"bwcellpmargin\">\n            <b>n=59<\/b>\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\" colspan=\"4\">\n<p class=\"bwcellpmargin\">\n            <b>Pem\/Carbo<\/b>\n<\/p>\n<p class=\"bwcellpmargin\">\n            <b>n=62<\/b>\n          <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl bwsinglebottom\">\n          <b>Adverse Reaction<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            <b>All Grades*<\/b>\n<\/p>\n<p class=\"bwcellpmargin\">\n            <b>(%)<\/b>\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            <b>Grade 3-4<\/b>\n<\/p>\n<p class=\"bwcellpmargin\">\n            <b>(%)<\/b>\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            <b>All Grades<\/b>\n<\/p>\n<p class=\"bwcellpmargin\">\n            <b>(%)<\/b>\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            <b>Grade 3-4<\/b>\n<\/p>\n<p class=\"bwcellpmargin\">\n            <b>(%)<\/b>\n          <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl bwsinglebottom\" colspan=\"13\">\n          <b>General Disorders and Administration Site Conditions<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignt bwalignl bwsinglebottom\">\n          Fatigue\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          71\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          3.4\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          50\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignt bwalignl bwsinglebottom\">\n          Peripheral Edema\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          22\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          18\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl bwsinglebottom\" colspan=\"13\">\n          <b>Gastrointestinal Disorders<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignt bwalignl bwsinglebottom\">\n          Nausea\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          68\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          1.7\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          56\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignt bwalignl bwsinglebottom\">\n          Constipation\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          51\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          37\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          1.6\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignt bwalignl bwsinglebottom\">\n          Vomiting\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          39\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          1.7\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          27\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignt bwalignl bwsinglebottom\">\n          Diarrhea\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          37\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          1.7\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          23\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          1.6\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl bwsinglebottom\" colspan=\"13\">\n          <b>Skin and Subcutaneous Tissue Disorders<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignt bwalignl bwsinglebottom\">\n          Rash<sup>\u2020<\/sup>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          42\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          1.7\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          21\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          1.6\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignt bwalignl bwsinglebottom\">\n          Pruritus\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          24\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          4.8\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignt bwalignl bwsinglebottom\">\n          Alopecia\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          20\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          3.2\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl bwsinglebottom\" colspan=\"13\">\n          <b>Respiratory, Thoracic and Mediastinal Disorders<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignt bwalignl bwsinglebottom\">\n          Dyspnea\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          39\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          3.4\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          21\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignt bwalignl bwsinglebottom\">\n          Cough\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          24\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          18\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl bwsinglebottom\" colspan=\"13\">\n          <b>Metabolism and Nutrition Disorders<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignt bwalignl bwsinglebottom\">\n          Decreased Appetite\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          31\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          23\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl bwsinglebottom\" colspan=\"13\">\n          <b>Nervous System Disorders<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignt bwalignl bwsinglebottom\">\n          Headache\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          31\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          16\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          1.6\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignt bwalignl bwsinglebottom\">\n          Dizziness\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          24\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          16\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignt bwalignl bwsinglebottom\">\n          Dysgeusia\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          20\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          11\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl bwsinglebottom\" colspan=\"13\">\n          <b>Psychiatric Disorders<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignt bwalignl bwsinglebottom\">\n          Insomnia\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          24\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          15\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl bwsinglebottom\" colspan=\"13\">\n          <b>Infections and Infestations<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignt bwalignl bwsinglebottom\">\n          Upper respiratory tract infection\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          20\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          3.2\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl bwsinglebottom\" colspan=\"13\">\n          <b>Musculoskeletal and Connective Tissue Disorders<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignt bwalignl bwsinglebottom\">\n          Arthralgia\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          15\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          24\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          1.6\n        <\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tbody>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">\n          *\n        <\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">\n          Graded per NCI CTCAE v4.0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">\n          <sup>\u2020<\/sup>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">\n          Includes rash, rash generalized, rash macular, rash maculo-papular,<br \/>\n          and rash pruritic.\n        <\/td>\n<\/tr>\n<tr>\n<td colspan=\"3\">\n          &nbsp;\n        <\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>\n      When administering KEYTRUDA in combination with pem\/carbo, KEYTRUDA<br \/>\n      should be administered first prior to chemotherapy when given on the<br \/>\n      same day. In metastatic NSCLC, KEYTRUDA is approved at a fixed dose of<br \/>\n      200 mg administered as an intravenous infusion over 30 minutes every<br \/>\n      three weeks until disease progression, unacceptable toxicity, or up to<br \/>\n      24 months in patients without disease progression; pemetrexed and<br \/>\n      carboplatin should be administered according to their FDA-approved<br \/>\n      labels.\n    <\/p>\n<p>\n      <b>About KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b> (pembrolizumab) Injection<\/b>\n    <\/p>\n<p>\n      KEYTRUDA is an anti-PD-1 therapy that works by increasing the ability of<br \/>\n      the body\u2019s immune system to help detect and fight tumor cells. KEYTRUDA<br \/>\n      is a humanized monoclonal antibody that blocks the interaction between<br \/>\n      PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes<br \/>\n      which may affect both tumor cells and healthy cells.\n    <\/p>\n<p>\n      Studies of KEYTRUDA \u2013 from the largest immuno-oncology program in the<br \/>\n      industry with more than 450 trials \u2013 include a wide variety of cancers<br \/>\n      and treatment settings. The KEYTRUDA clinical program seeks to<br \/>\n      understand factors that predict a patient\u2019s likelihood of benefitting<br \/>\n      from treatment with KEYTRUDA, including the exploration of several<br \/>\n      different biomarkers across a broad range of tumors.\n    <\/p>\n<p>\n      <b>KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b> (pembrolizumab)<\/b> <b>Indications<br \/>\n      and Dosing<\/b>\n    <\/p>\n<p>\n      <i>Melanoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with unresectable or<br \/>\n      metastatic melanoma at a dose of 2 mg\/kg every three weeks until disease<br \/>\n      progression or unacceptable toxicity.\n    <\/p>\n<p>\n      <i>Lung Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA, as a single agent, is indicated for the first-line treatment<br \/>\n      of patients with metastatic non-small cell lung cancer (NSCLC) whose<br \/>\n      tumors have high PD-L1 expression [tumor proportion score (TPS) \u226550%] as<br \/>\n      determined by an FDA-approved test, with no EGFR or ALK genomic tumor<br \/>\n      aberrations.\n    <\/p>\n<p>\n      KEYTRUDA, as a single agent, is also indicated for the treatment of<br \/>\n      patients with metastatic NSCLC whose tumors express PD-L1 (TPS \u22651%) as<br \/>\n      determined by an FDA-approved test, with disease progression on or after<br \/>\n      platinum-containing chemotherapy. Patients with EGFR or ALK genomic<br \/>\n      tumor aberrations should have disease progression on FDA-approved<br \/>\n      therapy for these aberrations prior to receiving KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA, in combination with pemetrexed and carboplatin, is indicated<br \/>\n      for the first-line treatment of patients with metastatic nonsquamous<br \/>\n      NSCLC. This indication is approved under accelerated approval based on<br \/>\n      tumor response rate and progression-free survival. Continued approval<br \/>\n      for this indication may be contingent upon verification and description<br \/>\n      of clinical benefit in the confirmatory trials.\n    <\/p>\n<p>\n      In metastatic NSCLC, KEYTRUDA is administered at a fixed dose of 200 mg<br \/>\n      every three weeks until disease progression, unacceptable toxicity, or<br \/>\n      up to 24 months in patients without disease progression.\n    <\/p>\n<p>\n      When administering KEYTRUDA in combination with chemotherapy, KEYTRUDA<br \/>\n      should be administered prior to chemotherapy when given on the same day.<br \/>\n      See also the Prescribing Information for pemetrexed and carboplatin.\n    <\/p>\n<p>\n      <i>Head and Neck Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with recurrent or<br \/>\n      metastatic head and neck squamous cell carcinoma (HNSCC) with disease<br \/>\n      progression on or after platinum-containing chemotherapy. This<br \/>\n      indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials. In HNSCC, KEYTRUDA is<br \/>\n      administered at a fixed dose of 200 mg every three weeks until disease<br \/>\n      progression, unacceptable toxicity, or up to 24 months in patients<br \/>\n      without disease progression.\n    <\/p>\n<p>\n      <i>Classical Hodgkin Lymphoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA (pembrolizumab) is indicated for the treatment of adult and<br \/>\n      pediatric patients with refractory classical Hodgkin lymphoma (cHL), or<br \/>\n      who have relapsed after three or more prior lines of therapy. This<br \/>\n      indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials. In adults with cHL,<br \/>\n      KEYTRUDA is administered at a fixed dose of 200 mg every three weeks<br \/>\n      until disease progression or unacceptable toxicity, or up to 24 months<br \/>\n      in patients without disease progression. In pediatric patients with cHL,<br \/>\n      KEYTRUDA is administered at a dose of 2 mg\/kg (up to a maximum of 200<br \/>\n      mg) every three weeks until disease progression or unacceptable<br \/>\n      toxicity, or up to 24 months in patients without disease progression.\n    <\/p>\n<p>\n      <b>Selected Important Safety Information for KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup>&nbsp;<b>(pembrolizumab)<\/b>\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated pneumonitis, including fatal cases.<br \/>\n      Pneumonitis occurred in 94 (3.4%) of 2799 patients receiving KEYTRUDA,<br \/>\n      including Grade 1 (0.8%), 2 (1.3%), 3 (0.9%), 4 (0.3%), and 5 (0.1%)<br \/>\n      pneumonitis, and occurred more frequently in patients with a history of<br \/>\n      prior thoracic radiation (6.9%) compared to those without (2.9%).<br \/>\n      Monitor patients for signs and symptoms of pneumonitis. Evaluate<br \/>\n      suspected pneumonitis with radiographic imaging. Administer<br \/>\n      corticosteroids for Grade 2 or greater pneumonitis. Withhold KEYTRUDA<br \/>\n      for Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4 or<br \/>\n      recurrent Grade 2 pneumonitis.\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated colitis. Colitis occurred in 48<br \/>\n      (1.7%) of 2799 patients receiving KEYTRUDA, including Grade 2 (0.4%), 3<br \/>\n      (1.1%), and 4 (&lt;0.1%) colitis. Monitor patients for signs and symptoms<br \/>\n      of colitis. Administer corticosteroids for Grade 2 or greater colitis.<br \/>\n      Withhold KEYTRUDA for Grade 2 or 3; permanently discontinue KEYTRUDA for<br \/>\n      Grade 4 colitis.\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated hepatitis. Hepatitis occurred in 19<br \/>\n      (0.7%) of 2799 patients receiving KEYTRUDA, including Grade 2 (0.1%), 3<br \/>\n      (0.4%), and 4 (&lt;0.1%) hepatitis. Monitor patients for changes in liver<br \/>\n      function. Administer corticosteroids for Grade 2 or greater hepatitis<br \/>\n      and, based on severity of liver enzyme elevations, withhold or<br \/>\n      discontinue KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA can cause hypophysitis. Hypophysitis occurred in 17 (0.6%) of<br \/>\n      2799 patients receiving KEYTRUDA, including Grade 2 (0.2%), 3 (0.3%),<br \/>\n      and 4 (&lt;0.1%) hypophysitis. Monitor patients for signs and symptoms of<br \/>\n      hypophysitis (including hypopituitarism and adrenal insufficiency).<br \/>\n      Administer corticosteroids and hormone replacement as clinically<br \/>\n      indicated. Withhold KEYTRUDA (pembrolizumab) for Grade 2; withhold or<br \/>\n      discontinue for Grade 3 or 4 hypophysitis.\n    <\/p>\n<p>\n      KEYTRUDA can cause thyroid disorders, including hyperthyroidism,<br \/>\n      hypothyroidism, and thyroiditis. Hyperthyroidism occurred in 96 (3.4%)<br \/>\n      of 2799 patients receiving KEYTRUDA, including Grade 2 (0.8%) and 3<br \/>\n      (0.1%) hyperthyroidism. Hypothyroidism occurred in 237 (8.5%) of 2799<br \/>\n      patients receiving KEYTRUDA, including Grade 2 (6.2%) and 3 (0.1%)<br \/>\n      hypothyroidism. Thyroiditis occurred in 16 (0.6%) of 2799 patients<br \/>\n      receiving KEYTRUDA, including Grade 2 (0.3%) thyroiditis. Monitor<br \/>\n      patients for changes in thyroid function (at the start of treatment,<br \/>\n      periodically during treatment, and as indicated based on clinical<br \/>\n      evaluation) and for clinical signs and symptoms of thyroid disorders.<br \/>\n      Administer replacement hormones for hypothyroidism and manage<br \/>\n      hyperthyroidism with thionamides and beta-blockers as appropriate.<br \/>\n      Withhold or discontinue KEYTRUDA for Grade 3 or 4 hyperthyroidism.\n    <\/p>\n<p>\n      KEYTRUDA can cause type 1 diabetes mellitus, including diabetic<br \/>\n      ketoacidosis, which have been reported in 6 (0.2%) of 2799 patients.<br \/>\n      Monitor patients for hyperglycemia or other signs and symptoms of<br \/>\n      diabetes. Administer insulin for type 1 diabetes, and withhold KEYTRUDA<br \/>\n      and administer antihyperglycemics in patients with severe hyperglycemia.\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated nephritis. Nephritis occurred in 9<br \/>\n      (0.3%) of 2799 patients receiving KEYTRUDA, including Grade 2 (0.1%), 3<br \/>\n      (0.1%), and 4 (&lt;0.1%) nephritis. Monitor patients for changes in renal<br \/>\n      function. Administer corticosteroids for Grade 2 or greater nephritis.<br \/>\n      Withhold KEYTRUDA for Grade 2; permanently discontinue KEYTRUDA for<br \/>\n      Grade 3 or 4 nephritis.\n    <\/p>\n<p>\n      KEYTRUDA can cause other clinically important immune-mediated adverse<br \/>\n      reactions. For suspected immune-mediated adverse reactions, ensure<br \/>\n      adequate evaluation to confirm etiology or exclude other causes. Based<br \/>\n      on the severity of the adverse reaction, withhold KEYTRUDA and<br \/>\n      administer corticosteroids. Upon improvement to Grade 1 or less,<br \/>\n      initiate corticosteroid taper and continue to taper over at least 1<br \/>\n      month. Based on limited data from clinical studies in patients whose<br \/>\n      immune-related adverse reactions could not be controlled with<br \/>\n      corticosteroid use, administration of other systemic immunosuppressants<br \/>\n      can be considered. Resume KEYTRUDA when the adverse reaction remains at<br \/>\n      Grade 1 or less following corticosteroid taper. Permanently discontinue<br \/>\n      KEYTRUDA for any Grade 3 immune-mediated adverse reaction that recurs<br \/>\n      and for any life-threatening immune-mediated adverse reaction.\n    <\/p>\n<p>\n      The following clinically significant immune-mediated adverse reactions<br \/>\n      occurred in less than 1% (unless otherwise indicated) of 2799 patients:<br \/>\n      arthritis (1.5%), exfoliative dermatitis, bullous pemphigoid, rash<br \/>\n      (1.4%), uveitis, myositis, Guillain-Barr\u00e9 syndrome, myasthenia gravis,<br \/>\n      vasculitis, pancreatitis, hemolytic anemia, and partial seizures arising<br \/>\n      in a patient with inflammatory foci in brain parenchyma. In addition,<br \/>\n      myelitis and myocarditis were reported in other clinical trials,<br \/>\n      including classical Hodgkin lymphoma, and postmarketing use.\n    <\/p>\n<p>\n      Solid organ transplant rejection has been reported in postmarketing use<br \/>\n      of KEYTRUDA (pembrolizumab). Treatment with KEYTRUDA may increase the<br \/>\n      risk of rejection in solid organ transplant recipients. Consider benefit<br \/>\n      of treatment with KEYTRUDA vs the risk of possible organ rejection in<br \/>\n      these patients.\n    <\/p>\n<p>\n      KEYTRUDA can cause severe or life-threatening infusion-related<br \/>\n      reactions, which have been reported in 6 (0.2%) of 2799 patients.<br \/>\n      Monitor patients for signs and symptoms of infusion-related reactions,<br \/>\n      including rigors, chills, wheezing, pruritus, flushing, rash,<br \/>\n      hypotension, hypoxemia, and fever. For Grade 3 or 4 reactions, stop<br \/>\n      infusion and permanently discontinue KEYTRUDA.\n    <\/p>\n<p>\n      Immune-mediated complications, including fatal events, occurred in<br \/>\n      patients who underwent allogeneic hematopoietic stem cell<br \/>\n      transplantation (HSCT) after being treated with KEYTRUDA. Of 23&nbsp;patients<br \/>\n      with cHL who proceeded to allogeneic HSCT after treatment with KEYTRUDA<br \/>\n      on any trial, 6&nbsp;patients (26%) developed graft-versus-host-disease<br \/>\n      (GVHD), one of which was fatal, and 2&nbsp;patients (9%) developed severe<br \/>\n      hepatic veno-occlusive disease (VOD) after reduced-intensity<br \/>\n      conditioning, one of which was fatal. Cases of fatal hyperacute GVHD<br \/>\n      after allogeneic HSCT have also been reported in patients with lymphoma<br \/>\n      who received a PD-1 receptor blocking antibody before transplantation.<br \/>\n      These complications may occur despite intervening therapy between PD-1<br \/>\n      blockade and allogeneic HSCT. Follow patients closely for early evidence<br \/>\n      of transplant-related complications such as hyperacute GVHD, severe<br \/>\n      (Grade&nbsp;3&nbsp;to&nbsp;4) acute GVHD, steroid-requiring febrile syndrome, hepatic<br \/>\n      VOD, and other immune-mediated adverse reactions, and intervene promptly.\n    <\/p>\n<p>\n      Based on its mechanism of action, KEYTRUDA can cause fetal harm when<br \/>\n      administered to a pregnant woman. If used during pregnancy, or if the<br \/>\n      patient becomes pregnant during treatment, apprise the patient of the<br \/>\n      potential hazard to a fetus. Advise females of reproductive potential to<br \/>\n      use highly effective contraception during treatment and for 4 months<br \/>\n      after the last dose of KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA monotherapy was discontinued due to adverse reactions in 8% of<br \/>\n      682 patients with metastatic NSCLC. The most common adverse event<br \/>\n      resulting in permanent discontinuation of KEYTRUDA was pneumonitis<br \/>\n      (1.8%). Adverse reactions leading to interruption of KEYTRUDA occurred<br \/>\n      in 23% of patients; the most common (\u22651%) were diarrhea (1%), fatigue<br \/>\n      (1.3%), pneumonia (1%), liver enzyme elevation (1.2%), decreased<br \/>\n      appetite (1.3%), and pneumonitis (1%). The most common adverse reactions<br \/>\n      (occurring in at least 20% of patients and at a higher incidence than<br \/>\n      with docetaxel) were decreased appetite (25% vs 23%), dyspnea (23% vs<br \/>\n      20%), and nausea (20% vs 18%).\n    <\/p>\n<p>\n      When KEYTRUDA (pembrolizumab) was administered in combination with<br \/>\n      pemetrexed and carboplatin, KEYTRUDA was discontinued in 10% of 59<br \/>\n      patients. The most common adverse reaction resulting in discontinuation<br \/>\n      of KEYTRUDA (\u22652%) was acute kidney injury (3.4%). Adverse reactions<br \/>\n      leading to interruption of KEYTRUDA occurred in 39% of patients; the<br \/>\n      most common (\u22652%) were fatigue (8%), neutrophil count decreased (8%),<br \/>\n      anemia (5%), dyspnea (3.4%), and pneumonitis (3.4%).The most common<br \/>\n      adverse reactions (\u226520%) with KEYTRUDA compared to carbo\/pem alone were<br \/>\n      fatigue (71% vs 50%), nausea (68% vs 56%), constipation (51% vs 37%),<br \/>\n      rash (42% vs 21%), vomiting (39% vs 27%), dyspnea (39% vs 21%), diarrhea<br \/>\n      (37% vs 23%), decreased appetite (31% vs. 23%), headache (31% vs 16%),<br \/>\n      cough (24% vs 18%), dizziness (24%vs 16%), insomnia (24% vs 15%),<br \/>\n      pruritus (24% vs 4.8%), peripheral edema (22% vs 18%), dysgeusia (20% vs<br \/>\n      11%), alopecia (20% vs 3.2%), upper respiratory tract infection (20% vs<br \/>\n      3.2%), and arthralgia (15% vs 24%). The study was not designed to<br \/>\n      demonstrate a statistically significant difference in adverse reaction<br \/>\n      rates for KEYTRUDA plus chemotherapy, as compared to chemotherapy alone,<br \/>\n      for any specified adverse reaction.\n    <\/p>\n<p>\n      It is not known whether KEYTRUDA is excreted in human milk. Because many<br \/>\n      drugs are excreted in human milk, instruct women to discontinue nursing<br \/>\n      during treatment with KEYTRUDA and for 4 months after the final dose.\n    <\/p>\n<p>\n      <b>Our Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into innovative oncology<br \/>\n      medicines to help people with cancer worldwide. At Merck, helping people<br \/>\n      fight cancer is our passion and supporting accessibility to our cancer<br \/>\n      medicines is our commitment. Our focus is on pursuing research in<br \/>\n      immuno-oncology and we are accelerating every step in the journey \u2013 from<br \/>\n      lab to clinic \u2013 to potentially bring new hope to people with cancer.\n    <\/p>\n<p>\n      As part of our focus on cancer, Merck is committed to exploring the<br \/>\n      potential of immuno-oncology with one of the fastest-growing development<br \/>\n      programs in the industry. We are currently executing an expansive<br \/>\n      research program that includes more than 450 clinical trials evaluating<br \/>\n      our anti-PD-1 therapy across more than 30 tumor types. We also continue<br \/>\n      to strengthen our immuno-oncology portfolio through strategic<br \/>\n      acquisitions and are prioritizing the development of several promising<br \/>\n      immunotherapeutic candidates with the potential to improve the treatment<br \/>\n      of advanced cancers.\n    <\/p>\n<p>\n      For more information about our oncology clinical trials, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;esheet=51556931&amp;newsitemid=20170510006682&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;index=1&amp;md5=60eb7e3fc04f59d55ca09d1aea2f2f51\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck Access Program for KEYTRUDA<\/b>\n    <\/p>\n<p>\n      At Merck, we are committed to supporting accessibility to our cancer<br \/>\n      medicines. Merck provides multiple programs to help ensure that<br \/>\n      appropriate patients who are prescribed KEYTRUDA (pembrolizumab) have<br \/>\n      access to our anti-PD-1 therapy. The Merck Access Program provides<br \/>\n      reimbursement support for patients receiving KEYTRUDA, including<br \/>\n      information to help with out-of-pocket costs and co-pay assistance for<br \/>\n      eligible patients. Merck also offers free product through our patient<br \/>\n      assistance program to eligible patients, primarily the uninsured, who,<br \/>\n      without our assistance, could not afford their medicine. More<br \/>\n      information is available by calling 1-855-257-3932 or visiting <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.merckaccessprogram-keytruda.com&amp;esheet=51556931&amp;newsitemid=20170510006682&amp;lan=en-US&amp;anchor=www.merckaccessprogram-keytruda.com&amp;index=2&amp;md5=af393263e187d50d7b06a781d3c12e01\" rel=\"nofollow\">www.merckaccessprogram-keytruda.com<\/a>.\n    <\/p>\n<p>\n      <b>About Merck\u2019s Patient Support Program for KEYTRUDA<\/b>\n    <\/p>\n<p>\n      Merck is committed to helping provide patients and their caregivers<br \/>\n      support throughout their treatment with KEYTRUDA. The KEY+YOU Patient<br \/>\n      Support Program provides a range of resources and services. For further<br \/>\n      information and to sign up, patients and physicians may call 85-KEYTRUDA<br \/>\n      (855-398-7832) or visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.keytruda.com&amp;esheet=51556931&amp;newsitemid=20170510006682&amp;lan=en-US&amp;anchor=www.keytruda.com&amp;index=3&amp;md5=509886b4edf76d1e0c19c324b9035d36\" rel=\"nofollow\">www.keytruda.com<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For more than a century, Merck, a leading global biopharmaceutical<br \/>\n      company known as MSD outside of the United States and Canada, has been<br \/>\n      bringing forward medicines and vaccines for many of the world&#8217;s most<br \/>\n      challenging diseases. Through our prescription medicines, vaccines,<br \/>\n      biologic therapies and animal health products, we work with customers<br \/>\n      and operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      health care through far-reaching policies, programs and partnerships.<br \/>\n      Today, Merck continues to be at the forefront of research to advance the<br \/>\n      prevention and treatment of diseases that threaten people and<br \/>\n      communities around the world &#8211; including cancer, cardio-metabolic<br \/>\n      diseases, emerging animal diseases, Alzheimer&#8217;s disease and infectious<br \/>\n      diseases including HIV and Ebola. For more information, visit&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Findex.html&amp;esheet=51556931&amp;newsitemid=20170510006682&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=4&amp;md5=0d7b047d4e4bb4719877c5b669b4c317\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and&nbsp;connect with us on&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51556931&amp;newsitemid=20170510006682&amp;lan=en-US&amp;anchor=Twitter&amp;index=5&amp;md5=e3cadd0ea8f5e2e910b11a9ac5bb43d9\" rel=\"nofollow\">Twitter<\/a>,&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FMerckInvents%2F&amp;esheet=51556931&amp;newsitemid=20170510006682&amp;lan=en-US&amp;anchor=Facebook&amp;index=6&amp;md5=7bc0a5addb1fad6a670381dcd38e8300\" rel=\"nofollow\">Facebook<\/a>,&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Fmerck%2F&amp;esheet=51556931&amp;newsitemid=20170510006682&amp;lan=en-US&amp;anchor=Instagram&amp;index=7&amp;md5=7d2f0240ed3c669b87fcdc5fbfa541b0\" rel=\"nofollow\">Instagram<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51556931&amp;newsitemid=20170510006682&amp;lan=en-US&amp;anchor=YouTube&amp;index=8&amp;md5=47f9035d0026e1d62cc83dbe1894746b\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51556931&amp;newsitemid=20170510006682&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=9&amp;md5=e4033387543a4dc01ff56fb8bbed772b\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2016 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=51556931&amp;newsitemid=20170510006682&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=10&amp;md5=44eca66cbd48d919e2d586b263d94ba1\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for KEYTRUDA (pembrolizumab) at&nbsp;<\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;esheet=51556931&amp;newsitemid=20170510006682&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;index=11&amp;md5=6b5449d9a0901438a27f48b36b9b18df\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf<\/b><br \/>\n<\/a><br \/>\n<b>&nbsp;and<\/b>\n    <\/p>\n<p>\n      <b>Patient Information\/Medication Guide for KEYTRUDA at&nbsp;<\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;esheet=51556931&amp;newsitemid=20170510006682&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;index=12&amp;md5=33c9251cdf387367487a066e90b9fa03\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf<\/b><br \/>\n<\/a><br \/>\n<b>.<\/b>\n    <\/p>\n<p>\n      Alimta<sup>\u00ae<\/sup>&nbsp;is a registered trademark of Eli Lilly and Company.\n    <\/p>\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20170510006682r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><br \/>\n<span class=\"bwct31415\"><br \/>\n<\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pamela Eisele, 267-305-3558<br \/>or<br \/>Investors:<br \/>Teri        Loxam, 908-740-1986     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>First Approval for an Anti-PD-1 Therapy as a Combination in Metastatic Nonsquamous NSCLC Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA\u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, in combination with pemetrexed (brand name Alimta\u00ae) and carboplatin (pem\/carbo), a commonly used chemotherapy regimen, for the first-line treatment of metastatic nonsquamous NSCLC, irrespective of PD-L1 expression. Under the FDA\u2019s accelerated approval regulations, this indication is approved based on tumor response rate and progression-free survival (PFS). Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. The approval was based on data from KEYNOTE-021, Cohort G1, in 123 previously untreated patients with metastatic nonsquamous NSCLC with no EGFR or ALK genomic tumor aberrations and irrespective of PD-L1<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,55,289],"class_list":["post-745556","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-prescription-medicine-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>FDA Approves Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) as First-Line Combination Therapy with Pemetrexed and Carboplatin for Patients with Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC), Irrespective of PD-L1 Expression - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-mercks-keytruda-pembrolizumab-as-first-line-combination-therapy-with-pemetrexed-and-carboplatin-for-patients-with-metastatic-nonsquamous-non-small-cell-lung-cancer-nsclc\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA Approves Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) as First-Line Combination Therapy with Pemetrexed and Carboplatin for Patients with Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC), Irrespective of PD-L1 Expression - Merck.com\" \/>\n<meta property=\"og:description\" content=\"First Approval for an Anti-PD-1 Therapy as a Combination in Metastatic Nonsquamous NSCLC Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA\u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, in combination with pemetrexed (brand name Alimta\u00ae) and carboplatin (pem\/carbo), a commonly used chemotherapy regimen, for the first-line treatment of metastatic nonsquamous NSCLC, irrespective of PD-L1 expression. Under the FDA\u2019s accelerated approval regulations, this indication is approved based on tumor response rate and progression-free survival (PFS). Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. The approval was based on data from KEYNOTE-021, Cohort G1, in 123 previously untreated patients with metastatic nonsquamous NSCLC with no EGFR or ALK genomic tumor aberrations and irrespective of PD-L1\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-mercks-keytruda-pembrolizumab-as-first-line-combination-therapy-with-pemetrexed-and-carboplatin-for-patients-with-metastatic-nonsquamous-non-small-cell-lung-cancer-nsclc\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:26:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"21 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-approves-mercks-keytruda-pembrolizumab-as-first-line-combination-therapy-with-pemetrexed-and-carboplatin-for-patients-with-metastatic-nonsquamous-non-small-cell-lung-cancer-nsclc\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-approves-mercks-keytruda-pembrolizumab-as-first-line-combination-therapy-with-pemetrexed-and-carboplatin-for-patients-with-metastatic-nonsquamous-non-small-cell-lung-cancer-nsclc\\\/\",\"name\":\"FDA Approves Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) as First-Line Combination Therapy with Pemetrexed and Carboplatin for Patients with Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC), Irrespective of PD-L1 Expression - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2017-05-10T16:39:00+00:00\",\"dateModified\":\"2025-11-07T06:26:32+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-approves-mercks-keytruda-pembrolizumab-as-first-line-combination-therapy-with-pemetrexed-and-carboplatin-for-patients-with-metastatic-nonsquamous-non-small-cell-lung-cancer-nsclc\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-approves-mercks-keytruda-pembrolizumab-as-first-line-combination-therapy-with-pemetrexed-and-carboplatin-for-patients-with-metastatic-nonsquamous-non-small-cell-lung-cancer-nsclc\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-approves-mercks-keytruda-pembrolizumab-as-first-line-combination-therapy-with-pemetrexed-and-carboplatin-for-patients-with-metastatic-nonsquamous-non-small-cell-lung-cancer-nsclc\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FDA Approves Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) as First-Line Combination Therapy with Pemetrexed and Carboplatin for Patients with Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC), Irrespective of PD-L1 Expression\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FDA Approves Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) as First-Line Combination Therapy with Pemetrexed and Carboplatin for Patients with Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC), Irrespective of PD-L1 Expression - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-mercks-keytruda-pembrolizumab-as-first-line-combination-therapy-with-pemetrexed-and-carboplatin-for-patients-with-metastatic-nonsquamous-non-small-cell-lung-cancer-nsclc\/","og_locale":"en_US","og_type":"article","og_title":"FDA Approves Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) as First-Line Combination Therapy with Pemetrexed and Carboplatin for Patients with Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC), Irrespective of PD-L1 Expression - Merck.com","og_description":"First Approval for an Anti-PD-1 Therapy as a Combination in Metastatic Nonsquamous NSCLC Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA\u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, in combination with pemetrexed (brand name Alimta\u00ae) and carboplatin (pem\/carbo), a commonly used chemotherapy regimen, for the first-line treatment of metastatic nonsquamous NSCLC, irrespective of PD-L1 expression. Under the FDA\u2019s accelerated approval regulations, this indication is approved based on tumor response rate and progression-free survival (PFS). Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. The approval was based on data from KEYNOTE-021, Cohort G1, in 123 previously untreated patients with metastatic nonsquamous NSCLC with no EGFR or ALK genomic tumor aberrations and irrespective of PD-L1","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-mercks-keytruda-pembrolizumab-as-first-line-combination-therapy-with-pemetrexed-and-carboplatin-for-patients-with-metastatic-nonsquamous-non-small-cell-lung-cancer-nsclc\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:26:32+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"21 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-mercks-keytruda-pembrolizumab-as-first-line-combination-therapy-with-pemetrexed-and-carboplatin-for-patients-with-metastatic-nonsquamous-non-small-cell-lung-cancer-nsclc\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-mercks-keytruda-pembrolizumab-as-first-line-combination-therapy-with-pemetrexed-and-carboplatin-for-patients-with-metastatic-nonsquamous-non-small-cell-lung-cancer-nsclc\/","name":"FDA Approves Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) as First-Line Combination Therapy with Pemetrexed and Carboplatin for Patients with Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC), Irrespective of PD-L1 Expression - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2017-05-10T16:39:00+00:00","dateModified":"2025-11-07T06:26:32+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-mercks-keytruda-pembrolizumab-as-first-line-combination-therapy-with-pemetrexed-and-carboplatin-for-patients-with-metastatic-nonsquamous-non-small-cell-lung-cancer-nsclc\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-mercks-keytruda-pembrolizumab-as-first-line-combination-therapy-with-pemetrexed-and-carboplatin-for-patients-with-metastatic-nonsquamous-non-small-cell-lung-cancer-nsclc\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-mercks-keytruda-pembrolizumab-as-first-line-combination-therapy-with-pemetrexed-and-carboplatin-for-patients-with-metastatic-nonsquamous-non-small-cell-lung-cancer-nsclc\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"FDA Approves Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) as First-Line Combination Therapy with Pemetrexed and Carboplatin for Patients with Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC), Irrespective of PD-L1 Expression"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"fb026d0a-ecdc-4528-a9aa-8ee443d79b58","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/FDA-Approves-Mercks-KEYTRUDA-pembrolizumab-as-First-Line-Combination-Therapy-with-Pemetrexed-and-Carboplatin-for-Patients-with-Metast-19CIZ.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745556","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745556\/revisions"}],"predecessor-version":[{"id":3674921,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745556\/revisions\/3674921"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745556"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745556"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}